No Data
No Data
Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?
China Securities Co.,Ltd: Accelerating development of the self-immunity market to promote the improvement and efficiency of the domestic innovative drug industry.
The patient population with autoimmune diseases and type II inflammation is growing rapidly, the market size is second only to cancer drugs, but still in a period of accelerated development. Existing drugs still have huge room for improvement in efficacy and safety.
Hong Kong stocks anomaly | Zai Lab (09688) rose more than 3% again. Recently, it announced that its Egamod subcutaneous injection was approved domestically in collaboration with Argenx.
Zai Lab (09688) rose more than 3% again. As of press time, it rose 3.50% to HKD 14.78, with a turnover of HKD 9.3122 million.
Express News | Argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection for Generalized Myasthenia Gravis in China
Asian Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Tuesday Trading
HKEX News | Zai Lab (09688) rose over 4% in the afternoon, as Edaravone Injection was approved domestically for the treatment of generalized myasthenia gravis.
Zai Lab (09688) rose more than 4% in the afternoon and at the time of publication, it rose 3.64%, at HKD 14.24, with a turnover of HKD 29.885 million.
No Data